Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Inhibrx intends FDA submission after phase 2 bone cancer win
Ozekibart reduced the risk of disease progression or death by 52% compared to placebo and more than doubled median progression-free survival.
Darren Incorvaia
Oct 24, 2025 6:40am
Ventyx's CV drug rapidly reduces cardio risk biomarker
Oct 23, 2025 9:45am
Moderna scraps congenital virus program after vax fails ph. 3
Oct 22, 2025 5:15pm
Arcturus' stock halves on cystic fibrosis readout
Oct 22, 2025 1:01pm
Alector halves staff after GSK-partnered antibody fails in ph. 3
Oct 22, 2025 11:23am
Sanofi's $1.7B bet beats CSL's Zemaira in phase 2 face-off
Oct 22, 2025 10:35am
